Cibus, Inc. Announces European Parliament Releases Draft Report On The Proposal For The Regulation Of Plants Obtained From New Genomic Techniques
Portfolio Pulse from Benzinga Newsdesk
Cibus, Inc. (NASDAQ:CBUS), an agricultural technology company, has acknowledged the European Parliament's draft report on the proposal for regulation of plants obtained from New Genomic Techniques (NGTs). The proposal supports the introduction of a new regulation on plants obtained by NGTs and identifies a 'Conventional-like' category of NGT products. This would bring EU policy closer to that of trading partners in North and South America, Australia, and Japan. Products from Cibus' gene editing platform, such as disease-resistant canola and oilseed rape, would be considered 'Conventional-like'.

November 06, 2023 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The European Parliament's draft report on the regulation of plants obtained from New Genomic Techniques (NGTs) could have a positive impact on Cibus, Inc. (NASDAQ:CBUS). The proposal identifies a 'Conventional-like' category of NGT products, which would include products from Cibus' gene editing platform.
The draft report supports the introduction of a new regulation on plants obtained by NGTs, which includes products from Cibus' gene editing platform. This could potentially open up new markets for Cibus in the EU, aligning EU policy with that of other major trading partners. This could lead to increased demand for Cibus' products, potentially driving up the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100